NORCROSS, Ga., March 09, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.D., the Company's chief operating officer, will present at the 29th Annual ROTH Conference on Wednesday, March 15, 2017 at 11:30 a.m. Pacific Time....
Research done in partnership with San Antonio Military Medical Center showed an average 50% PASI reduction by end of 24-week treatment period NORCROSS, Ga., March 06, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced results from an explorat...
NORCROSS, Ga., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.D., the Company's chief operating officer, will present at BIO CEO & Investor Conference on Monday, February 13, 2017 at 3:00 p.m. Eastern time. The...
NORCROSS, Ga., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and the Providence Cancer Center today announced the presentation of preclinical and early clinical data from two investigator-initiated Phase 1 clinical trials of GR-MD-02 used in combina...
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation NORCROSS, Ga., Feb. 6, 2017 /CNW/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the February 2nd presenta...
NORCROSS, Ga., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has generated sufficient financing to cover currently planned expenditures through 2017 and it remains on track to present top line data from its NASH-CX Phase 2 clinica...
The Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com NORCROSS, Ga., Jan. 30, 2017 /CNW/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Trabe...
NORCROSS, Ga., Dec. 29, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has recently completed a private placement of its common stock, raising $3,000,000 in new funding. In a separate transaction, the Company also closed an additional sal...
NORCROSS, Ga., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company will present a corporate update via live webcast immediately following the business portion of its 2016
Meaningful activity of GR-MD-02 in treating psoriasis and preliminary data in treating atopic dermatitis suggests promise in treatment of serious skin disease
NORCROSS, Ga., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three and nine months ended September 30, 2016.
NORCROSS, Ga., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the company's president, chief executive officer and chief medical
Research to be presented at The Liver Meeting® 2016 demonstrates correlation of FibroScan and MRE as non-invasive tests to assess the progression of liver fibrosis and cirrhosis
Larger Phase 2b clinical trial in NASH cirrhosis (NASH-CX) now completely enrolled Closed private placement financing for $1.5 million Conference call to be held today at 5:30 p.m. (Eastern Time) NORCOSS, Ga., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.
NORCROSS, Ga., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the Company's president, chief executive officer and chief
Meaningful activity of GR-MD-02 in treating psoriasis suggests promise in treatment of non-alcoholic steatohepatitis (NASH), the company's primary target
Top-line data from NASH-FX trial in NASH patients with advanced fibrosis expected to be reported by the end of September Australian patent allowance strengthens global intellectual property franchise NORCROSS, Ga., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.
NORCROSS, Ga., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the completion of patient recruitment in its Phase 2 clinical trial with GR-MD-02 in patients with
A significant clearing of psoriasis in first four patients prompts the extension of treatment for an additional 12 weeks Conference call to be held tomorrow at 9:00 a.m. Eastern time NORCROSS, Ga., May 16, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.
NORCROSS, Ga., May 10, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three months ended March 31, 2016.
NORCROSS, Ga., May 05, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, has received notification that its collaborative abstract with investigators at Augusta University "Galectin-3
NORCROSS, Ga., April 07, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the Company's president, chief executive officer and chief
NORCROSS, Ga., March 07, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces today Peter G. Traber, M.D., the Company's president, chief executive officer and chief medical
NORCROSS, Ga. , Feb. 24, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for
NORCROSS, Ga., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today Peter G. Traber, MD, the Company's president, chief executive officer and chief medical
NORCROSS, Ga., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today Peter Traber, M.D., the Company's president, chief executive officer and chief medical
NORCROSS, Ga., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the election of Marc Rubin, M.D. as Chairman of the Board of Directors. Dr.
NORCROSS, Ga., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that the year-in-review post "2015-2016, Progress and Possibilities" is now available on the
Forum Uniquely Brings Together Leading Family Offices, Their Foundations and Sovereign Wealth Fund Representatives Seeking Impact Investment, Grant-Giving, and Philanthropy Opportunities Within Health and Life Sciences
Second Trial in GR-MD-02 Phase 2 Program Features Non-Invasive Endpoints and Shorter Treatment Duration; Data Readout Expected in the Third Quarter of 2016
Broad Coverage Includes Use of Various Pectin Compounds for Chronic Kidney Disease Associated with the Development of Fibrosis, Established Kidney Fibrosis, Chronic Lung Disease Associated with the Development of Fibrosis and Established Lung Fibrosis
